CN1296088C - 一种治疗儿童急性咽炎的药物及其制备方法 - Google Patents
一种治疗儿童急性咽炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN1296088C CN1296088C CNB2004100374190A CN200410037419A CN1296088C CN 1296088 C CN1296088 C CN 1296088C CN B2004100374190 A CNB2004100374190 A CN B2004100374190A CN 200410037419 A CN200410037419 A CN 200410037419A CN 1296088 C CN1296088 C CN 1296088C
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- medicine
- radix bupleuri
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 25
- 208000016150 acute pharyngitis Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 11
- 229940079593 drug Drugs 0.000 title description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims abstract description 13
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims abstract description 13
- 229960003321 baicalin Drugs 0.000 claims abstract description 13
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims description 27
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 11
- 238000000151 deposition Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 7
- 235000008216 herbs Nutrition 0.000 abstract 2
- 239000002547 new drug Substances 0.000 abstract 2
- 241000758794 Asarum Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 240000006740 Cichorium endivia Species 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000014676 Phragmites communis Nutrition 0.000 abstract 1
- NEZONWMXZKDMKF-SNVBAGLBSA-N Shikonin Chemical compound C1=CC(O)=C2C(=O)C([C@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-SNVBAGLBSA-N 0.000 abstract 1
- 235000010716 Vigna mungo Nutrition 0.000 abstract 1
- 240000001417 Vigna umbellata Species 0.000 abstract 1
- 235000011453 Vigna umbellata Nutrition 0.000 abstract 1
- 244000137773 Viola philippica Species 0.000 abstract 1
- 235000003733 chicria Nutrition 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 238000003809 water extraction Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 75
- 230000000202 analgesic effect Effects 0.000 description 69
- 210000003800 pharynx Anatomy 0.000 description 64
- 238000004140 cleaning Methods 0.000 description 62
- 241000894006 Bacteria Species 0.000 description 44
- 239000011550 stock solution Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 230000037396 body weight Effects 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 description 9
- 244000052616 bacterial pathogen Species 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 208000033809 Suppuration Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000194017 Streptococcus Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- KVYRCBOUKXJXDK-UHFFFAOYSA-N 3,4-dimethylphenazine-1,2-diamine hydrochloride Chemical compound Cl.C1=CC=CC2=NC3=C(C)C(C)=C(N)C(N)=C3N=C21 KVYRCBOUKXJXDK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 241000261238 bacterium 1.5 Species 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 药物浓度(g生药/ml) | 杯数 | 抑菌圈直径(mm) | ||||
金葡菌(10-3) | 甲链菌(10-1) | 乙链菌(10-1) | 表皮菌(1-3) | 绿脓菌(10-3) | |||
儿童清咽解热口服液 | 0.60 | 40 | △△△***8.5±2.49 | △△△***7.2±3.31 | △△△***6.0±2.85 | ***6.3±3.17 | 0±0.00 |
1.1 | 40 | △△△***14.0±2.97 | △△△***11.3±2.08 | △△△***10.0±1.78 | △△△***12.2±2.11 | 8.9±0.76 | |
2.2 | 40 | △△△***19.6±3.28 | △△***14.9±2.43 | △△△***14.4±1.70 | △△△***17.7±2.61 | △△△***8.7±0.67 | |
小儿清热解毒口服液 | 0.25ml原液/ml | 40 | ***4.5±3.46 | ***3.4±3.47 | **1.5±2.63 | ***6.8±2.71 | 0±0.00 |
0.50ml原液/ml | 40 | ***8.0±2.55 | ***6.4±3.59 | ***7.4±0.86 | ***9.5±1.32 | 0±0.00 | |
1.00ml原液/ml | 40 | ***10.7±3.16 | ***9.7±2.57 | ***9.5±2.04 | ***12.1±1.42 | 0±0.00 | |
NS | ------- | 40 | 0±0.00 | 0±0.00 | 0±0.00 | 0±0.00 | 0±0.00 |
组别 | 药物浓度(g生药/ml) | 杯数 | 抑菌圈直径(mm) | ||||
金葡菌(10-3) | 甲链菌(10-1) | 乙链菌(10-1) | 表皮菌(10-3) | 绿脓菌(10-3) | |||
儿童清咽解热口服液 | 0.60 | 30 | △△△***10.2±3.13 | △△△***5.2±3.55 | △△△***4.7±4.26 | △△△***9.3±3.24 | 0±0.00 |
1.1 | 30 | △△△***15.3±3.17 | △△△***10.5±1.46 | △△△***10.3±1.42 | △△△***15.1±2.73 | △△△***8.9±0.76 | |
2.2 | 30 | △△△***19.8±3.29 | △△△***13.6±1.22 | △△△***13.8±1.57 | △△△***19.7±2.80 | △△△***11.9±1.61 | |
小儿清热解毒口服液 | 0.25ml原液/ml | 30 | ***4.1±3.74 | 0±0.00 | 0±0.00 | ***3.6±3.72 | 0±0.00 |
0.50ml原液/ml | 30 | ***8.6±1.33 | ***2.4±3.50 | ***2.4±3.50 | ***7.0±3.33 | 0±0.00 | |
1.00ml原液/ml | 30 | ***11.0±1.92 | ***8.5±1.61 | ***8.5±1.48 | ***11.3±1.35 | 0±0.00 | |
NS | ------- | 30 | 0±0.00 | 0±0.00 | 0±0.00 | 0±0.00 | 0±0.00 |
菌种 | 儿童清咽解热口服液 | 小儿清热解毒口服液 | ||||
标准菌 | 分离致病菌 | 标准菌 | 分离致病菌 | |||
最高稀释倍数 | g生药/ml | 最高稀释倍数 | g生药/ml | 最高稀释倍数 | 最高稀释倍数 | |
金葡萄 | 0.0125 | 0.03 | 0.025 | 0.06 | 0.05 | 0 |
甲链菌 | 0.10 | 0.22 | 0.1 | 0.22 | 0 | 0 |
乙链菌 | 0.05 | 0.11 | 0.1 | 0.22 | 0 | 0 |
表皮菌 | 0.05 | 0.11 | 0.125 | 0.28 | 0.1 | 0.1 |
绿脓菌 | 0 | 0 | 0 | 0 | 0 | 0 |
菌种 | 儿童清咽解热口服液 | 小儿清热解毒口服液 | ||||
标准菌 | 分离致病菌 | 标准菌 | 分离致病菌 | |||
最高稀释倍数 | g生药/ml | 最高稀释倍数 | g生药/ml | 最高稀释倍数 | 最高稀释倍数 | |
金葡萄 | 0.0063 | 0.01 | 0.0125 | 0.030 | 0.025 | 0.1 |
甲链菌 | 0.05 | 0.11 | 0.05 | 0.11 | 0 | 0 |
乙链菌 | 0.025 | 0.060 | 0.05 | 0.11 | 0 | 0 |
表皮菌 | 0.025 | 0.060 | 0.0063 | 0.01 | 0.05 | 0.05 |
绿脓菌 | 0 | 0 | 0.1 | 0.22 | 0 | 0 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 死亡(只) | 存活(只) | 死亡率% | |
空白对照组 | ------ | 15 | 13 | 2 | 86.6 | |
儿童清咽解热口服液 | 小 | 5.0 | 15 | 10 | 5 | 66.7 |
大 | 15.0 | 15 | 6 | 9 | 40.0* | |
小儿清热解毒口服液 | 6.8mg原液/kg | 15 | 11 | 4 | 73.3 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 死亡(只) | 存活(只) | 死亡率% | |
空白对照组 | ------ | 29 | 28 | 1 | 96.6 | |
儿童清咽解热口服液 | 小 | 5.0 | 27 | 24 | 3 | 88.9 |
大 | 15.0 | 27 | 19 | 8 | 70.4* | |
小儿清热解毒口服液 | 6.8mg原液/kg | 27 | 20 | 7 | 74.1* |
组别 | 剂量(g生药/kg) | 鼠数(只) | 死亡(只) | 存活(只) | 死亡率% | |
空白对照组 | ------ | 20 | 19 | 1 | 95.0 | |
儿童清咽解热口服液 | 小 | 5.0 | 19 | 13 | 6 | 68.4 |
大 | 15.0 | 19 | 12 | 7 | 63.2* | |
小儿清热解毒口服液 | 6.8mg原液/kg | 19 | 15 | 4 | 78.9 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 死亡 | 存活 | |||
只 | % | 只 | 天( X±S.D) | ||||
空白对照组 | ------ | 14 | 11 | 78.6 | 3 | 8.6±3.03 | |
儿童清咽解热口服液 | 小 | 5.0 | 14 | 10 | 71.4 | 4 | 9.9±2.80 |
大 | 15.0 | 14 | 9 | 64.3 | 5 | 9.9±3.22 | |
病毒唑 | 0.14g/kg | 14 | 0 | ***0 | 14 | ***14±0.00 | |
正常对照组 | ------ | 14 | 0 | 0 | 14 | 14±0.00 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 重量(mg) | 肿胀抑制率(%) | |||
左耳 | 右耳 | 两耳差 | |||||
空白对照组 | ------ | 10 | 16.1±1.09 | 38.3±3.86 | 22.1±3.15 | ||
儿童清咽解热口服液 | 小 | 7.5 | 10 | 16.7±1.86 | 35.7±6.11 | 19.0±6.27 | 14.0 |
大 | 15.0 | 10 | 17.1±1.83 | 32.5±5.02 | **15.3±5.26 | 30.7 | |
小儿清热解毒口服液 | 6.8ml原液/kg | 10 | 16.2±1.61 | 33.9±5.47 | *17.6±5.14 | 20.4 | |
正常对照组 | 0.2g/kg | 10 | 16.3±0.95 | 29.9±5.42 | ***13.7±5.06 | 38.0 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 渗出液 | ||
ml | 光密度(O.D) | ||||
空白对照组 | ------ | 10 | 0.25±0.060 | 0.182±0.029 | |
儿童清咽解热口服液 | 小 | 7.5 | 10 | 0.16±0.066** | 0.109±0.023** |
大 | 15 | 10 | 0.16±0.045** | 0.107±0.033** | |
小儿清热解毒口服液 | 6.8ml原液/kg | 10 | 0.21±0.032 | 0.164±0.046 | |
阿斯匹林 | 0.2g/kg | 10 | 0.17±0.032** | 0.119±0.043** |
组别 | 剂量(g生药/kg) | 兔数(只) | 正常体温(℃) | 致热给药后体温升高值(℃) | ||||||
1° | 2° | 3° | 4° | 5° | 6° | |||||
空白对照组 | ------ | 5 | 39.0 | 1.53±0.22 | 2.04±0.48 | 2.25±0.37 | 1.99±0.28 | 1.34±0.25 | 0.88±0.31 | |
儿童清咽解热口服液 | 小 | 7.5 | 5 | 39.1 | *1.18±0.19 | 1.74±0.21 | 1.87±0.20 | *1.40±0.18 | *0.91±0.28 | 0.55±0.17 |
大 | 15 | 5 | 39.1 | *0.81±0.49 | *1.33±0.21 | *1.65±0.17 | **1.23±0.40 | 0.65±0.52 | **△0.09±0.38 | |
小儿清热解毒口服液 | 6.8ml原液/kg | 5 | 39.0 | *1.13±0.24 | *1.51±0.17 | *1.83±0.10 | *1.39±0.22 | *0.92±0.27 | 0.52±0.29 | |
阿斯匹林 | 0.2g/kg | 5 | 39.1 | ***0.41±0.08 | ***0.23±0.10 | ***0.13±0.10 | ***0.11±0.09 | ***0.15±0.09 | ***0.14±0.10 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 扭体次数/10分 |
空白对照组 | ------ | 12 | 48.0±13.7 |
儿童清咽解热口服液 | 5.0 | 12 | 33.8±9.7** |
儿童清咽解热口服液 | 10.0 | 12 | 32.4±9.7** |
儿童清咽解热口服液 | 15.0 | 12 | 27.7±7.4*** |
小儿清热解毒口服液 | 4.5ml原液/kg | 12 | 32.8±9.6** |
阿斯匹林 | 0.2g/kg | 12 | 7.5±6.8*** |
组别 | 剂量(g生药/kg) | 鼠数(只) | 痛阀(秒) | |||||
给药前 | 给药后 | |||||||
30′ | 1h | 1.5h | 2.5h | |||||
空白对照组 | ------ | 13 | 14.4±5.2 | 13.6±5.4 | 16.1±6.9 | 16.1±5.5 | 22.2±13.4 | |
儿童清咽解热口服液 | 小 | 5.0 | 14 | 14.9±3.6 | △22.0±11.7 | △25.3±10.9 | △27.6±9.5 | 30.4±16.7 |
大 | 10.0 | 14 | 14.4±3.8 | 17.3±12.9 | △27.1±17.1 | △31.5±16.9 | △37.1±18.6 | |
小儿清热解毒口服液 | 2.3ml原液/kg | 14 | 13.6±5.3 | 20.4±14.6 | △27.5±15.4 | △32.3±4.0 | △33.6±14.6 | |
阿斯匹林 | 0.2g/kg | 14 | 12.9±4.1 | △26.1±18.3 | 22.6±13.4 | △24.4±11.7 | 24.3±11.3 |
组别 | 剂量(g生药/kg) | 鼠数(只) | 光密度(O.D) |
空白对照组 | ------ | 10 | 0.028±0.014 |
儿童清咽解热口服液 | 5.0 | 10 | 0.026±0.011 |
儿童清咽解热口服液 | 15.0 | 10 | 0.046±0.008△△ |
小儿清热解毒口服液 | 6.8ml原液/kg | 10 | 0.083±0.017△△ |
组别 | 剂量(g生药/kg) | 鼠数(只) | 溶血素(O.D) |
空白对照组 | ------ | 10 | 0.419±0.073 |
儿童清咽解热口服液 | 5.0 | 10 | 0.594±0.212△ |
儿童清咽解热口服液 | 10.0 | 10 | 0.659±0.182 |
儿童清咽解热口服液 | 15.0 | 10 | 0.843±0.428△△ |
小儿清热解毒口服液 | 6.8ml原液/kg | 10 | 0.519±0.128△△ |
人参煎剂 | 2.0 | 10 | 0.653±0.211△△ |
组别 | 剂量(g生药/kg) | 鼠数(只) | 重量(mg) | ||
左耳 | 右耳 | 两耳差 | |||
正常对照组 | ------ | 10 | 14.0±1.15 | 17.8±1.75 | 4.1±2.22 |
儿童清咽解热口服液 | 5.0 | 10 | 13.7±1.25 | 19.3±3.62 | 4.6±1.4 |
儿童清咽解热口服液 | 10.0 | 10 | 13.9±1.29 | 21.7±4.50 | 7.8±5.0 |
儿童清咽解热口服液 | 15.0 | 10 | 14.0±1.70 | 22.3±4.85 | 8.3±5.3△ |
小儿清热解毒口服液 | 6.8ml原液/kg | 10 | 13.7±2.00 | 20.7±3.33 | 7.0±2.7△ |
人参煎剂 | 2.0 | 10 | 14.0±1.56 | 20.8±2.97 | 6.9±2.8△ |
组别 | 例数 | 痊愈 | 显效 | 有效 | 无效 | 痊愈率% | 显效率% | 有效率% |
试验组对照组小计 | 210106316 | 15651207 | 423577 | 91524 | 358 | 74.348.165.5 | 94.381.189.9 | 98.695.397.5 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100374190A CN1296088C (zh) | 2004-04-30 | 2004-04-30 | 一种治疗儿童急性咽炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100374190A CN1296088C (zh) | 2004-04-30 | 2004-04-30 | 一种治疗儿童急性咽炎的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1689627A CN1689627A (zh) | 2005-11-02 |
CN1296088C true CN1296088C (zh) | 2007-01-24 |
Family
ID=35345581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100374190A Expired - Lifetime CN1296088C (zh) | 2004-04-30 | 2004-04-30 | 一种治疗儿童急性咽炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1296088C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108956835B (zh) * | 2017-05-19 | 2022-02-25 | 亚宝药业集团股份有限公司 | 一种清咽解热口服药物的指纹图谱检测方法 |
CN110251619A (zh) * | 2019-08-02 | 2019-09-20 | 亚宝药业四川制药有限公司 | 一种治疗小儿急性咽炎的口服液及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1480191A (zh) * | 2003-07-09 | 2004-03-10 | 石世德 | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 |
-
2004
- 2004-04-30 CN CNB2004100374190A patent/CN1296088C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1480191A (zh) * | 2003-07-09 | 2004-03-10 | 石世德 | 一种预防和治疗肺炎、支气管炎、咽炎及上呼吸道感染的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1689627A (zh) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1840122A (zh) | 止咳化痰的中药制剂及其生产方法 | |
CN105287790B (zh) | 一种鸡矢藤提取物及其应用 | |
CN111407817A (zh) | 一种预防呼吸道感染病原微生物的中药组合物及其制备方法 | |
CN1682842A (zh) | 一种消炎解毒的中药组合物及其制备方法和用途 | |
CN1733079A (zh) | 治疗和预防呼吸道病毒感染的药物组合物及其制备与用途 | |
CN1723955A (zh) | 射干提取物及其制备方法和用途 | |
CN1943675A (zh) | 清热化痰、止咳平喘的藏药药物组合物及其制备方法 | |
CN1857362A (zh) | 金感康药物制剂及其制备方法 | |
CN1296088C (zh) | 一种治疗儿童急性咽炎的药物及其制备方法 | |
CN101053600A (zh) | 治疗感冒的药物组合物及其制备方法和用途 | |
CN1513447A (zh) | 竹叶总黄酮在前列腺疾病防治药物及其保健食品中的应用 | |
CN1606979A (zh) | 黄芩素作为解热、镇痛、抗炎、抗菌、抗病毒剂的作用 | |
CN1323681C (zh) | 一种治疗上呼吸道感染的复方制剂及其在制药中的应用 | |
CN1814221A (zh) | 一种治疗尿路感染的中药组合物及其制备方法 | |
CN1323668C (zh) | 一种药物组合物及其制药用途 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN1686241A (zh) | 一种开口箭提取物、含有开口箭提取物的药物组合物及其制备方法和用途 | |
CN100337658C (zh) | 治疗感冒风热症的中药组合物及其制备方法 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
CN1089000C (zh) | 一种治疗鸡病的兽药 | |
CN106913670B (zh) | 促生长及强免疫的禽用中药生物制剂及其制备方法 | |
CN1919270A (zh) | 组合物,其提取物及它们的药物用途 | |
CN1742845A (zh) | 一种治疗呼吸系统疾患的中药组合物及其制备方法 | |
CN101077873A (zh) | 新的neo-克罗烷型二萜化合物及其应用 | |
CN1589892A (zh) | 一种治疗急、慢性咽炎的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Peng Shu Document name: Correction notice |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Peng Shu Document name: Deemed as a notice of withdrawal |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Peng Shu Document name: Resume right request approval decision |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO., LTD Free format text: FORMER NAME: BEIJING UNIVERSITY OF CHINESE MEDICINE PHARMACEUTICAL FACTORY |
|
CP01 | Change in the name or title of a patent holder |
Address after: 101300, Lin River Street, 24 Industrial Development Zone, Shunyi District, Beijing Patentee after: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO.,LTD. Address before: 101300, Lin River Street, 24 Industrial Development Zone, Shunyi District, Beijing Patentee before: PHARMACEUTICAL FACTORY OF BEIJ |
|
ASS | Succession or assignment of patent right |
Owner name: SHANXI YABAO PHARMACEUTICAL GROUP CORP. Free format text: FORMER OWNER: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO., LTD. Effective date: 20141010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 101300 SHUNYI, BEIJING TO: 044600 YUNCHENG, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141010 Address after: 044600 Fumin Road, Ruicheng County, Shanxi, China, No. 43, No. Patentee after: SHANXI YABAO PHARMACEUTICAL Group Corp. Address before: 101300, Lin River Street, 24 Industrial Development Zone, Shunyi District, Beijing Patentee before: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO.,LTD. |
|
DD01 | Delivery of document by public notice |
Addressee: Qiao Shuzhen Document name: Notification of Passing Examination on Formalities |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180411 Address after: 101300 24 Linhe street, Linke Industrial Development Zone, Shunyi District, Beijing. Patentee after: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO.,LTD. Address before: 044600 Fumin Road, Ruicheng County, Shanxi, China, No. 43, No. Patentee before: Shanxi Yabao Pharmaceutical Group Corp. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 101300 24 Lin He street, Linhe Industrial Development Zone, Shunyi District, Beijing Patentee after: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO.,LTD. Address before: 101300 24 Linhe street, Linke Industrial Development Zone, Shunyi District, Beijing. Patentee before: YABAO BEIZHONGDA (BEIJING) PHARMACEUTICAL CO.,LTD. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070124 |
|
CX01 | Expiry of patent term |